Gestational diabetes statistics: prevalence, risks, and what the data says about long-term outcomes

The glucose tolerance test at 24 weeks is a ritual of pregnancy that most women dread for its sugary orange drink and the hour of waiting. For most, it comes back normal and they move on. For the woman who gets the call that her numbers are high, the next several months change. She is now managing a condition that affects her pregnancy, her delivery, and (though she may not realize it yet) her health for decades afterward.

Gestational diabetes mellitus (GDM) is diabetes that develops during pregnancy in a woman who did not have diabetes before. It is driven by the hormonal changes of pregnancy, which increase insulin resistance in a way that some women's bodies cannot compensate for. The CDC estimates that GDM affects 2% to 10% of pregnancies in the United States annually. That range is broad because prevalence varies significantly by race, age, and the diagnostic criteria used. By most recent estimates, the actual rate is closer to 8% and climbing.

This article breaks down the latest data on who gets gestational diabetes, why rates are rising, what happens during and after pregnancy, and what the racial disparities in this condition look like.

How common is gestational diabetes

The CDC's current estimate is that gestational diabetes affects 2% to 10% of pregnancies in the United States each year. That wide range reflects differences in study populations and diagnostic criteria. Using the more sensitive International Association of Diabetes and Pregnancy Study Groups (IADPSG) criteria, prevalence is closer to 15% to 18% in some populations. Using the older Carpenter-Coustan criteria that ACOG endorses, it is roughly 6% to 9%.

With approximately 3.6 million live births per year in the U.S., even the conservative 6% estimate means more than 216,000 women develop gestational diabetes annually. At the higher end, the number exceeds 360,000.

A 2021 study by Shah et al. published in JAMA, which analyzed 12.6 million live births from 2011 to 2019 in the National Center for Health Statistics dataset, found that the overall GDM prevalence increased from 4.7% in 2011 to 6.3% in 2019 — a 30% relative increase over less than a decade. Among first live births, the rate was even higher.

Globally, the International Diabetes Federation estimates that approximately 16.7% of live births worldwide are affected by some form of hyperglycemia in pregnancy, with GDM accounting for the vast majority. That translates to roughly 21 million affected births per year.

Why prevalence keeps rising

The upward trend in gestational diabetes is not subtle. Multiple factors are contributing, and disentangling their individual effects is difficult.

Rising maternal age. Women in the United States are having children later. The average age at first birth was 27.3 in 2022, up from 24.9 in 2000. GDM risk increases with age: women over 35 have roughly 2 to 3 times the risk compared to women under 25. As the childbearing population ages, GDM prevalence rises mechanically.

Increasing rates of overweight and obesity. Pre-pregnancy BMI is one of the strongest predictors of gestational diabetes. The CDC reports that approximately 29% of women of reproductive age in the U.S. are obese (BMI ≥30). Obesity roughly triples the risk of GDM. The rising obesity rate among young women is directly fueling the GDM increase.

Changes in racial and ethnic composition. GDM prevalence varies substantially by race and ethnicity, and population shifts contribute to aggregate trends. This is not a commentary on biology — it reflects the intersection of genetics, diet, socioeconomic status, and healthcare access.

Broader diagnostic criteria. Some of the increase reflects changes in how GDM is diagnosed. The IADPSG criteria, adopted by some institutions following the HAPO study results, use lower glucose thresholds and therefore identify more women. Whether this reclassification improves outcomes or leads to overdiagnosis is an active area of debate.

If you are planning a pregnancy and want to understand your fertile window and cycle patterns, our ovulation calculator and cycle length calculator can help. But metabolic preparation (including weight management and glucose screening) is equally important in the preconception period.

Racial and ethnic disparities

Gestational diabetes does not affect all women equally. The 2021 JAMA study by Shah et al. documented pronounced disparities in GDM prevalence by race and ethnicity among U.S. women:

Non-Hispanic Asian women have the highest GDM prevalence by a substantial margin. Within that group, rates vary further: South Asian and Filipino women have among the highest rates of any subpopulation studied, often exceeding 15%. This elevated risk is partly attributed to lower thresholds for insulin resistance at lower BMI levels in Asian populations — a phenomenon sometimes described as the "metabolically obese, normal weight" phenotype.

American Indian and Alaska Native women also face disproportionate risk, reflecting high baseline rates of type 2 diabetes in these communities, limited access to prenatal care, and dietary factors tied to food insecurity and food desert geography.

The disparities are compounded by differences in screening and treatment. A 2020 analysis found that Black women with GDM were less likely to receive postpartum glucose testing (the test that catches progression to type 2 diabetes) than white women, even when controlling for insurance status and healthcare access. That gap has downstream consequences that accumulate for years.

Risks during pregnancy

The HAPO study (Hyperglycemia and Adverse Pregnancy Outcomes), published in the New England Journal of Medicine in 2008, was a landmark investigation that followed 25,505 pregnant women across 15 centers in nine countries. Its central finding was that the relationship between maternal glucose levels and adverse outcomes was continuous — there was no clear threshold below which risk vanished.

Higher maternal glucose levels were associated with increased rates of:

• Macrosomia (birth weight above the 90th percentile): 25% of GDM pregnancies result in a large-for-gestational-age infant, compared to roughly 10% in non-GDM pregnancies
• Cesarean delivery: women with GDM have a c-section rate approximately 25% to 35% higher than women without GDM
• Neonatal hypoglycemia: the baby's pancreas, accustomed to high glucose from the mother, overproduces insulin after birth, causing blood sugar drops in the first hours of life
• Preeclampsia: GDM increases preeclampsia risk by approximately 40% to 60%
• Shoulder dystocia: a serious delivery complication where the baby's shoulders become stuck, more common when the baby is large

Stillbirth risk is also modestly elevated in poorly controlled GDM, though modern management has substantially reduced this risk. The data on this is mixed — well-managed GDM does not appear to significantly increase stillbirth rates, but undiagnosed or undertreated cases carry meaningful excess risk.

If you are pregnant and tracking your due date, our IVF date calculator can help with timeline planning. For women with GDM, delivery timing (typically between 39 and 40 weeks for well-controlled cases, earlier for insulin-dependent cases) is an important discussion with your OB.

The type 2 diabetes pipeline

This is the statistic that stays with me: approximately 50% of women who have gestational diabetes will develop type 2 diabetes within 5 to 10 years after delivery.

A 2020 systematic review and meta-analysis by Vounzoulaki et al. published in the BMJ analyzed 20 studies involving more than 1 million women. The pooled relative risk of type 2 diabetes in women with a history of GDM was 9.51 compared to women without GDM. In absolute terms, about 16% to 20% developed type 2 diabetes within the first 5 years, and roughly 50% did so within 10 years.

That 10-fold relative risk makes GDM one of the strongest known predictors of future type 2 diabetes. Stronger than family history alone. Stronger than obesity alone.

The mechanism is straightforward. Pregnancy stress-tests the pancreas. Women who develop GDM have beta cells that could not produce enough insulin to overcome pregnancy-driven insulin resistance. After delivery, glucose levels typically normalize, but the underlying beta cell dysfunction persists. As the woman ages and insulin resistance increases naturally, the deficit reveals itself again — this time as permanent type 2 diabetes.

The tragedy is that postpartum glucose screening (which can catch prediabetes or early type 2 diabetes) is chronically underperformed. ACOG recommends that all women with GDM receive a 75-gram oral glucose tolerance test at 4 to 12 weeks postpartum. Studies consistently show that only 20% to 50% of eligible women complete this test. Some women are not told about it. Some are, but do not return for the appointment. The healthcare system loses them in the transition from obstetric care to primary care, and a window for early intervention closes.

Cardiovascular risk after GDM

The long-term consequences of gestational diabetes extend beyond type 2 diabetes. A 2019 systematic review and meta-analysis by Kramer et al. published in Diabetologia found that women with a history of GDM had approximately twice the risk of cardiovascular events (including coronary heart disease, stroke, and heart failure) compared to women without GDM.

The cardiovascular risk was elevated even in women who did not go on to develop type 2 diabetes, suggesting that GDM itself (or the metabolic dysfunction it represents) is an independent cardiovascular risk factor. A 2021 AHA scientific statement formally recognized adverse pregnancy outcomes, including GDM, as risk-enhancing factors that should be incorporated into cardiovascular risk assessment for women.

For a deeper look at how pregnancy complications connect to heart disease, our article on heart disease in women covers the broader data on pregnancy as a cardiovascular stress test.

The practical implication is that a woman who had gestational diabetes 15 years ago should not be treated as if her pregnancy was a discrete event with no ongoing consequences. Her doctor should know about it. Her cardiovascular risk factors should be monitored more closely. In most cases, they are not.

Screening and diagnosis

In the United States, ACOG recommends universal GDM screening between 24 and 28 weeks of gestation using a two-step approach:

1. Step 1: A 50-gram, one-hour glucose challenge test. If blood glucose at one hour is ≥130 or ≥140 mg/dL (the threshold varies by institution), the woman proceeds to step 2.
2. Step 2: A 100-gram, three-hour oral glucose tolerance test. GDM is diagnosed if two or more of four glucose values exceed defined thresholds (Carpenter-Coustan or National Diabetes Data Group criteria).

An alternative one-step approach, recommended by the International Association of Diabetes and Pregnancy Study Groups (IADPSG) and endorsed by the WHO, uses a 75-gram, two-hour test with lower thresholds. This approach identifies more women with GDM (roughly 18% of pregnancies versus 6% to 9% with the two-step method) but whether treating this larger group improves outcomes proportionally is debated.

Early screening (before 24 weeks) is recommended for women with risk factors: BMI ≥30, prior GDM, first-degree relative with diabetes, or membership in a high-risk racial/ethnic group. Women with very high glucose levels early in pregnancy may actually have preexisting type 2 diabetes that was undiagnosed before conception.

One area of active research is first-trimester risk prediction. Several groups are developing models that combine maternal characteristics, biomarkers (such as fasting glucose, HbA1c, and adipokines), and clinical history to identify women at high risk of GDM months before the standard screening window. If validated, these tools could allow earlier lifestyle intervention and potentially prevent some cases.

Management during pregnancy

The goal of GDM management is to keep maternal blood glucose within a target range that reduces fetal complications without causing maternal hypoglycemia. ACOG targets are: fasting glucose <95 mg/dL, one-hour postprandial <140 mg/dL, and two-hour postprandial <120 mg/dL.

For most women, management starts with medical nutrition therapy and physical activity. A diet that controls carbohydrate intake (not eliminates it) while providing adequate nutrition for pregnancy. The PCOS diet guide on our site covers related principles around insulin resistance and dietary management that have significant overlap.

About 15% to 30% of women with GDM require pharmacological treatment because diet and exercise alone cannot maintain target glucose levels. Insulin is the first-line pharmacological therapy recommended by ACOG. Metformin and glyburide are used as alternatives in some practices, though both cross the placenta and their long-term effects on offspring remain incompletely understood.

Blood glucose monitoring is a daily reality for women with GDM. Most are asked to check their glucose 4 times daily: fasting and after each meal. Continuous glucose monitoring (CGM) is being studied as an alternative, and several small trials have shown that CGM use in GDM can improve glycemic control and reduce the frequency of large-for-gestational-age births, though CGM is not yet standard of care for GDM.

Delivery timing depends on glycemic control. Well-controlled GDM managed with diet alone generally does not require induction before 40 to 41 weeks. GDM requiring insulin or with suboptimal control is typically delivered at 39 weeks. Early delivery, before 39 weeks, carries its own risks for the newborn and should be reserved for cases with clear maternal or fetal indication.

Frequently asked questions about gestational diabetes

How common is gestational diabetes?

Gestational diabetes affects 2% to 10% of U.S. pregnancies, with recent estimates closer to 7% to 8%, per the CDC. A 2021 JAMA study of 12.6 million live births found that prevalence increased by 30% between 2011 and 2019. Using broader IADPSG diagnostic criteria, prevalence can reach 15% to 18% in some populations.

Does gestational diabetes lead to type 2 diabetes?

Yes. Approximately 50% of women with gestational diabetes develop type 2 diabetes within 5 to 10 years after delivery, according to a 2020 BMJ meta-analysis. The relative risk of type 2 diabetes in women with prior GDM is about 9.5 times higher than in women without. Postpartum glucose testing at 4 to 12 weeks after delivery is recommended but completed by only 20% to 50% of eligible women.

Which racial groups have the highest gestational diabetes rates?

Non-Hispanic Asian women have the highest GDM prevalence in the United States at approximately 11.1%, per a 2021 JAMA analysis of 2019 birth data. American Indian and Alaska Native women (7.2%) and Hispanic women (6.6%) also have elevated rates. Within Asian subgroups, South Asian and Filipino women have among the highest prevalence, often exceeding 15%.

What are the risks of gestational diabetes for the baby?

Babies born to mothers with GDM face higher rates of macrosomia (large birth weight), neonatal hypoglycemia, shoulder dystocia during delivery, and admission to the neonatal intensive care unit. The HAPO study (NEJM, 2008) demonstrated a continuous relationship between maternal glucose and adverse outcomes, with higher glucose levels linked to progressively higher risk.

Does gestational diabetes increase heart disease risk?

Yes. A 2019 meta-analysis in Diabetologia by Kramer et al. found that women with prior GDM had approximately twice the risk of cardiovascular events, including coronary heart disease and stroke, compared to women without GDM. This risk was elevated even in women who did not develop type 2 diabetes, suggesting GDM is an independent cardiovascular risk factor.

How is gestational diabetes treated during pregnancy?

Treatment starts with dietary management and physical activity. ACOG targets are fasting glucose below 95 mg/dL, one-hour postprandial below 140 mg/dL, and two-hour postprandial below 120 mg/dL. About 15% to 30% of women need insulin to meet these targets. Blood glucose monitoring, typically four times daily, is standard. Delivery timing depends on glycemic control, with 39 weeks recommended for insulin-dependent cases.